Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA-ORBIT: Phase 3 Trial of Navenibart in Hereditary Angioedema
2025-521660-35-00Phase 3Authorised
- Sponsor
- Astria Therapeutics
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Navenibart with Placebo (2 arms). Primary endpoint: Number of time-normalized investigator-confirmed HAE attacks during the 6-month Treatment Period. Planned start Aug 2025; status: authorised.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2025-521660-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521660-35-00.